Preclinical and clinical evidence indicates that increased ALAS mRNA levels and consequent accumulation of ALA and PBG cause neurotoxicity and clinical manifestations in patients with AHP, although the exact relationship between elevated ALA/PBG and clinical manifestations is not understood [30, 44, 45]. The gene discussed is ALAS1; the disease is anhaptoglobinemia.